1Cacek AJ. Review of alterations in oral phenytoin bioavailability associated with formulation, antacids and foos. Ther Drug Monit,1986, 8: 166-171.
2Degen PH, Flech G, Cardot JM, et al. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. Biopharm Drug Dispos, 1994, 15: 519-526.
3Doose DR, Walker SA, Gisclon LG. Single - dose pharmacokinetic of food on the bioavailabilability of topiramate, a novel antiepileptic drug.J Clin Pharmacol, 1996, 36: 884-891.
4Perucca E, Richens A. General principles: biotransformation . In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptie drags. 4thed. New York: Raven Press, 1995, 31-50.
5Anderon GD. A mechanistic approach to antiepileptie drug interactions. Ann Pharmacother, 1998, 32: 554-563.
6Schater SC, Oxcarbazepine: current status and clinical aplications. Exp Opin Invest Drugs, 1999, 8:1103 - 1112.
7Baruzzi A, Albani F, Riva R, et al. Oxcarbazepine: phannacokinetic interaction and their clinical relevance. Epilepsia, 1993, 35: S14- 19.
8May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentration in epileptic patients with and without valproic acid comedication: results of a retro spective study. Ther Drug Monit, 1999, 21:1751-81.
9Anderson GD, Yau MK, Gidai BE, et el. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996;60:145 -56.
10Kerrick JM, Wolff DL, Graves NM. Predicting unbound phenytoin concentrations in patients receiving valproic acid: a comparisnn of two prediction methods. Ann Pharmacother 1995 ;29:470 - 4.
2Harden CL. The Co-morbidity of depression and epilepsy: epi- demiology, etiology, and treatment [J]. Neurology, 2002, 59 (Suppl 4) :$48-$55.
3Kanner AM, Cole AJ. Comorbid depressive disorders in epilep- sy[J]. CNSSpectr,2010, 15(2 suppl4):3-6.
4Kanner AM. Depression and epilepsy: a review of multiple fac- ets of their close Relation[J]. Neurol Clin,2009,27(4):865- 880.
5Kanner AM. Mood disorder and epilepsy: a neurobiologic per- spective of their relationship[J]. Dialogues in clinical neuro-science, 2008, 10(1): 39.
6Hasler G, Bonwetsch R, Giovacchini G, et al. 5-HT1A Recep tor Binding in Temporal Lobe Epilepsy Patients With and Without Major Depression[J]. Biological Psychiatry, 2007, 62 (11): 1 258 1 264.
7Savic I, Lindstr6m P, Gulyas B, et al. Limbic reductions of 5- HTaA receptor binding in human temporal lobe epilepsy[J]. Neurology, 2004, 62(8): 1 343-1 351.
8Giovacchini G, Toczek MT, Bonwetsch R, et al. 5-HTla re- ceptors are reduced in temporal lobe epilepsy after partial-vol- ume eorreetion[J]. Journal of Nuclear Medicine, 2005, 46(7) : 1 128-1 135.
9Gidal BE. Serotonin and epilepsy: The story continues[J]. Epilepsy Currents, 2013, 13(6) : 289-290.
10Sapolsky RM. The possibility of neurotoxicity in the hippo- campus in major depression: a primer on neuron death[J]. Biol Psychiatry, 2000,48(8): 755 765.
